Heterogeneous brain distribution of bumetanide following systemic administration in rats
Biopharmaceutics & Drug Disposition · 2024
DOI: 10.1002/bdd.2390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biopharmaceutics & Drug Disposition, 2024. Verfasst von Wolfgang Löscher und 2 weiteren Autor:innen. Beteiligte Einrichtung: Translational Neuropharmacology Laboratory, NIFE, Department of Experimental Otology of the ENT Clinics, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Bumetanide, Brain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Bumetanide is used widely as a tool and off‐label treatment to inhibit the Na‐K‐2Cl cotransporter NKCC1 in the brain and thereby to normalize intra‐neuronal chloride levels in several brain disorders. However, following systemic administration, bumetanide only poorly penetrates into the brain parenchyma and does not reach levels sufficient to inhibit NKCC1. The low brain penetration is a consequence of both the high ionization rate and plasma protein binding, which restrict brain entry by passive diffusion, and of brain efflux transport. In previous studies, bumetanide was determined in the whole brain or a few brain regions, such as the hippocampus. However, the blood–brain barrier and its efflux transporters are heterogeneous across brain regions, so it cannot be excluded that bumetanide reaches sufficiently high brain levels for NKCC1 inhibition in some discrete brain areas. Here, bumetanide was determined in 14 brain regions following i.v. administration of 10 mg/kg in rats. Because bumetanide is much more rapidly eliminated by rats than humans, its metabolism was reduced by pretreatment with piperonyl butoxide. Significant, up to 5‐fold differences in regional bumetanide levels were determined with the highest levels in the midbrain and olfactory bulb and the lowest levels in the striatum and amygdala. Brain:plasma ratios ranged between 0.004 (amygdala) and 0.022 (olfactory bulb). Regional brain levels were significantly correlated with local cerebral blood flow. However, regional bumetanide levels were far below the IC 50 (2.4 μM) determined previously for rat NKCC1. Thus, these data further substantiate that the reported effects of bumetanide in rodent models of brain disorders are not related to NKCC1 inhibition in the brain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Neuropharmacology Laboratory, NIFE, Department of Experimental Otology of the ENT Clinics, Hannover Medical School, Hannover, Germany.
- Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Hannover, Germany.
- Center for Systems Neuroscience Hannover, Hannover, Germany.
ORCID-Profile: Wolfgang Löscher
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Löscher, W., Gramer, M., & Römermann, K. (2024). Heterogeneous brain distribution of bumetanide following systemic administration in rats. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.2390
Vancouver
Löscher W, Gramer M, Römermann K. Heterogeneous brain distribution of bumetanide following systemic administration in rats. Biopharmaceutics & Drug Disposition. 2024. doi:10.1002/bdd.2390
BibTeX
@article{Lscher2024,
author = {Löscher, Wolfgang and Gramer, Martina and Römermann, Kerstin},
title = {Heterogeneous brain distribution of bumetanide following systemic administration in rats},
journal = {Biopharmaceutics & Drug Disposition},
year = {2024},
doi = {10.1002/bdd.2390}
}
EUVIMED